Author(s): Isacoff WH, Townsend CM, Eiber FR, Forster T, Morton DL, , Isacoff WH, Townsend CM, Eiber FR, Forster T, Morton DL,
Abstract Share this page
Abstract In clinical studies performed during 111 infusions of high dose methotrexate (MTX) we have evolved a clinical and laboratory protocol which permits such therapy without prohibitive risk to the patient. The plasma MTX data obtained indicate that pharmacokinetic disposition is dose related during these infusions and that such data are useful in identifying patients at risk from serious toxicity.
This article was published in Med Pediatr Oncol
and referenced in Journal of Drug Metabolism & Toxicology